Current Report Filing (8-k)
November 17 2020 - 8:01AM
Edgar (US Regulatory)
0001137883
false
0001137883
2020-11-17
2020-11-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 17, 2020
Brainstorm Cell Therapeutics Inc.
(Exact name of registrant as specified
in its charter)
Delaware
|
|
001-36641
|
|
20-7273918
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File No.)
|
|
(IRS Employer Identification No.)
|
1325 Avenue of Americas, 28th Floor
|
|
New York, NY
|
10019
|
(Address of principal executive offices)
|
(Zip Code)
|
(201) 488-0460
(Registrant’s telephone number,
including area code)
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.00005 par value
|
BCLI
|
NASDAQ Stock Market LLC
(Nasdaq Capital Market)
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
On November 17,
2020, Brainstorm Cell Therapeutics Inc. (the “Company”) issued a press release announcing Topline Results
from its NurOwn® Phase 3 ALS Study. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated
herein by reference.
The Company will
host a conference call and live webcast at 8:30 am ET on Tuesday, November 17, 2020 to discuss the Topline Results from
its NurOwn® Phase 3 ALS Study. A live webcast of the conference call may be accessed by visiting the Investors
& Media section of the Company’s website at http://www.ir.brainstorm-cell.com.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
BRAINSTORM CELL THERAPEUTICS INC.
|
|
|
|
Date: November 17, 2020
|
By:
|
/s/ Chaim Lebovits
|
|
|
Chaim Lebovits
|
|
Chief Executive Officer
|
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Apr 2023 to Apr 2024